At what enterprise value was ORGANOX acquired in 2023?

You can find the full valuation details of ORGANOX on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.5x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of ORGANOX when it was acquired by LAUXERA?

The exact EV/EBITDA multiple for ORGANOX is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.5x. Join our community for free to access full valuation data and industry trends.

When was ORGANOX acquired by LAUXERA?

ORGANOX was acquired by LAUXERA in 2023.

What was the revenue of ORGANOX at the time of the deal?

The revenue of ORGANOX at the time of the deal is estimated to be in the range of 10M - 30M GBP. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of ORGANOX during the acquisition?

ORGANOX's EBITDA is estimated to be in the range of 0M - 5M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the ORGANOX acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the ORGANOX deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://lauxera.com/lauxera-capital-partners-has-led-a-25m-growth-investment-into-organox/

← DATABASE

Home Database Healthcare & PharmaORGANOX

07/2023

LAUXERA

invests in

ORGANOX

UNITED KINGDOM Life Sciences / Medical Devices REV 10M - 30M GBP

LAUXERA invests in ORGANOX

UNITED KINGDOM Life Sciences / Medical Devices REV 10M - 30M GBP

Context

Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio. The investment thesis centers on funding the global scale-up and commercial acceleration of an established, market-leading medical device platform. OrganOx leverages a proprietary technology, normothermic machine perfusion, which has already supported over 2,500 liver transplants worldwide. The strategic rationale of the capital injection is focused on rapidly expanding OrganOx's commercial footprint and deeply institutionalizing its partnerships with tier-one transplant centers across the United States and Europe.

ORGANOX, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.5x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

OrganOx is a UK-based company founded in 2008, originating from the University of Oxford, which markets a groundbreaking device that can keep a liver graft functional outside the human body for up to 24 hours, significantly increasing the number of grafts eligible for transplantation. With innovative technology and a dedicated team, OrganOx has become a major player in the transplantation field, with a steadily growing revenue and established profitability, having generated a profit of £7.5 million in 2024. The company provides cutting-edge solutions to improve transplantation outcomes and meet the growing needs of patients. OrganOx is a success story in the medtech sector, with a history marked by strategic partnerships and targeted investments, such as the £25 million funding round led by Lauxera in 2023, and the $142 million funding round co-led by HealthQuest and Lauxera last February.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with ORGANOX

Date	Acquirer	Target	Country	Sector	Deal Context
08/2025	TERUMO	ORGANOX	UNITED KINGDOM	Life Sciences	Lauxera Capital Partners has successfully finalized the divestment of its minority equity stake in UK-based OrganOx to Japanese medical giant Terumo, marking the first historical exit for the medtech-focused growth investor. Since its initial entry into OrganOx’s capital by leading a £25 million funding round in 2023, followed by co-leading a $142 million expansion round in February 2025 alongside HealthQuest, Lauxera has successfully driven a five-fold increase in OrganOx’s revenue base within a two-year holding period. This rapid scale-up has generated a highly lucrative return on investment of over 100% for the growth sponsor. Strategically, this high-profile realization is positioned to significantly accelerate the institutional fundraising momentum for Lauxera’s second flagship vehicle, which targets €400 million with a hard cap of €500 million.

REFERENCES

Revenue range: 10M - 30M GBP

EBITDA range: 0M - 5M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ORGANOX by LAUXERA are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: organox

Acquirer: lauxera